Literature DB >> 11114713

Proliferation and apoptosis in the evolution of endemic and acquired immunodeficiency syndrome-related Kaposi's sarcoma.

E Kaaya1, E Castaños-Vélez, T Heiden, M Ekman, A I Catrina, J Kitinya, L Andersson, P Biberfeld.   

Abstract

Kaposi's sarcoma (KS) is a multifocal lesion that occurs predominantly in the skin, most frequently in people infected with HIV-1, and that evolves through early stages (patch and plaque) to a tumor-like late stage (nodular). Both, endemic African (EKS) and AIDS-associated (AKS) KS expressed human herpesvirus 8 (HHV-8) as shown by PCR. By immunohistochemistry the expression of cellular Bcl-2 and c-myc was confined in early stages of both EKS and AKS to relatively few endothelial cells (EC) whereas in nodular KS most of spindle cells (SC) strongly expressed both genes. CD40 was usually strongly expressed in SC at all KS stages as well as in EC of non-involved tissue whereas CD40L (CD154) was not demonstrable. Fas (CD95) was moderately to weakly expressed by SC whereas p53 and Waf-1 were found in less than 5% of the SC. In both AKS and EKS at nodular stage almost no apoptotic SC were detected. In most AKS and EKS low levels of cell proliferation were seen but AKS showed consistently higher values compared to EKS. All clinical types and stages of KS showed a diploid cellular DNA content by flow cytometric analysis of microselected lesions. Thus, we conclude that KS during evolution represents diploid, probably reactive, cell proliferation, which progressively increases the expression of strong cellular and also viral (HHV-8) antiapoptotic factors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11114713     DOI: 10.1007/bf02782199

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  23 in total

1.  Lymphoid disorders associated with HHV-8/KSHV infection: facts and contentions.

Authors:  G Gaidano; E Castaños-Velez; P Biberfeld
Journal:  Med Oncol       Date:  1999-04       Impact factor: 3.064

2.  The immunoexpression of bcl-2 and p53 in Kaposi's sarcoma.

Authors:  M A Dada; R Chetty; S C Biddolph; J W Schneider; K C Gatter
Journal:  Histopathology       Date:  1996-08       Impact factor: 5.087

3.  Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors.

Authors:  M Thome; P Schneider; K Hofmann; H Fickenscher; E Meinl; F Neipel; C Mattmann; K Burns; J L Bodmer; M Schröter; C Scaffidi; P H Krammer; M E Peter; J Tschopp
Journal:  Nature       Date:  1997-04-03       Impact factor: 49.962

4.  Expression of adhesion molecules in endemic and epidemic Kaposi's sarcoma.

Authors:  E E Kaaya; E Castaños-Velez; H Amir; L Lema; J Luande; J Kitinya; M Patarroyo; P Biberfeld
Journal:  Histopathology       Date:  1996-10       Impact factor: 5.087

5.  Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors.

Authors:  E Brambilla; A Negoescu; S Gazzeri; S Lantuejoul; D Moro; C Brambilla; J L Coll
Journal:  Am J Pathol       Date:  1996-12       Impact factor: 4.307

6.  Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma.

Authors:  Y Chang; E Cesarman; M S Pessin; F Lee; J Culpepper; D M Knowles; P S Moore
Journal:  Science       Date:  1994-12-16       Impact factor: 47.728

7.  CD40 antigen is expressed by endothelial cells and tumor cells in Kaposi's sarcoma.

Authors:  J Pammer; A Plettenberg; W Weninger; B Diller; M Mildner; A Uthman; W Issing; M Stürzl; E Tschachler
Journal:  Am J Pathol       Date:  1996-05       Impact factor: 4.307

8.  Ras, C-myc and C-erbB-2 oncoprotein expression in non-AIDS Mediterranean Kaposi's sarcoma.

Authors:  D A Spandidos; A Kaloterakis; M Yiagnisis; A Varatsos; J K Field
Journal:  Anticancer Res       Date:  1990 Nov-Dec       Impact factor: 2.480

9.  A role for a new herpes virus (KSHV) in different forms of Kaposi's sarcoma.

Authors:  M Schalling; M Ekman; E E Kaaya; A Linde; P Biberfeld
Journal:  Nat Med       Date:  1995-07       Impact factor: 53.440

10.  Overexpression of Bcl-2 in Kaposi's sarcoma-derived cells.

Authors:  T Simonart; C Degraef; J C Noel; D Fokan; L Zhou; O Pradier; M Ducarme; L Schandene; J P Van Vooren; D Parent; M Heenen
Journal:  J Invest Dermatol       Date:  1998-09       Impact factor: 8.551

View more
  6 in total

1.  Fibroblast Growth Factor-2 and the HIV-1 Tat Protein Synergize in Promoting Bcl-2 Expression and Preventing Endothelial Cell Apoptosis: Implications for the Pathogenesis of AIDS-Associated Kaposi's Sarcoma.

Authors:  Cecilia Sgadari; Giovanni Barillari; Clelia Palladino; Stefania Bellino; Brunella Taddeo; Elena Toschi; Barbara Ensoli
Journal:  Int J Vasc Med       Date:  2011-10-09

2.  KSHV/HHV-8 and HIV infection in Kaposi's sarcoma development.

Authors:  Pawan Pyakurel; Fatemeh Pak; Amos R Mwakigonja; Ephata Kaaya; Peter Biberfeld
Journal:  Infect Agent Cancer       Date:  2007-02-02       Impact factor: 2.965

3.  Insulin-like growth factor-I receptor activity is essential for Kaposi's sarcoma growth and survival.

Authors:  S-B Catrina; M Lewitt; C Massambu; A Dricu; J Grünler; M Axelson; P Biberfeld; K Brismar
Journal:  Br J Cancer       Date:  2005-04-25       Impact factor: 7.640

Review 4.  Clonality, Mutation and Kaposi Sarcoma: A Systematic Review.

Authors:  Blanca Iciar Indave Ruiz; Subasri Armon; Reiko Watanabe; Lesley Uttley; Valerie A White; Alexander J Lazar; Ian A Cree
Journal:  Cancers (Basel)       Date:  2022-02-25       Impact factor: 6.639

5.  Viral oncogene-induced DNA damage response is activated in Kaposi sarcoma tumorigenesis.

Authors:  Sonja Koopal; Johanna H Furuhjelm; Annika Järviluoma; Sari Jäämaa; Pawan Pyakurel; Christel Pussinen; Maria Wirzenius; Peter Biberfeld; Kari Alitalo; Marikki Laiho; Päivi M Ojala
Journal:  PLoS Pathog       Date:  2007-09-07       Impact factor: 6.823

Review 6.  Human immunodeficiency virus-1 (HIV-1)-mediated apoptosis: new therapeutic targets.

Authors:  Zukile Mbita; Rodney Hull; Zodwa Dlamini
Journal:  Viruses       Date:  2014-08-19       Impact factor: 5.048

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.